Cipla Limited
Nippon India Mutual Fund increased its stake in Cipla Limited from 1.69% to 1.96%, purchasing 2,151,502 shares. This transaction increased their total holdings to 15,766,895 shares.
A leading pharmaceutical manufacturer, Cipla develops and markets branded and generic formulations alongside active pharmaceutical ingredients across multiple therapeutic areas. Established in 1935, the company operates manufacturing facilities across India and internationally, serving both domestic and global markets. Cipla's distinctive strength lies in its integrated business model combining formulation development with API production, enabling cost-efficient drug manufacturing, distribution, and accessibility to patients worldwide.
India's fifth-largest AMC with over Rs 6 lakh crore in AUM, backed by Japan's Nippon Life Insurance which holds majority stake. Formerly Reliance MF, rebranded in 2019 after Nippon's acquisition. Sailesh Raj Bhan has run the equity book for over two decades and is one of India's most experienced active managers. Known for sector rotational calls and a deep research bench.